Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients

Indian Journal of Pharmaceutical Sciences

Volumn 71, Issue 4, 2009, Pages 359-370

  Yadav, A V ^a   Shete, A S ^b   Dabke, A P ^c   Kulkarni, P V ^d   Sakhare, S S ^e  

^a Krishna Institute of Medical Scinces   (India)

^b Shree Santkrupa College of Pharmacy   (India)

^c Government College of Pharmacy   (India)

^d GOVERNMENT COLLEGE OF PHARMACY   (India)

^e Gourishankar Education Society's   (India)

Author keywords

Bioavailability; Crystal form; Dissolution; Drug solubility; Physicochemical property

Indexed keywords

2 PROPANOL; 2,4,6 TRINITROBENZOIC ACID; 5 NITROURACIL; ACECLOFENAC; ACETIC ACID; ACETONE; ALCOHOL; ARIPIPRAZOLE; BARBITURIC ACID DERIVATIVE; BENZOIC ACID; CARBAMAZEPINE; CHITOSAN; CYANURIC ACID; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUOXETINE; FUMARIC ACID; IBUPROFEN; INDOLEACETIC ACID; ITRACONAZOLE; MALEIC ACID; MALIC ACID; MALONIC ACID; MELAMINE; N,N BIS(4 BROMOPHENYL)MELAMINE DIETHYLBARBITAL; OXALIC ACID; PROPYLENE GLYCOL; SACCHARIN; SILDENAFIL; SPIRONOLACTONE; SUCCINIC ACID; TENOFOVIR DISOPROXIL; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DERIVATIVE;

ASTHMA; COCRYSTAL; CRYSTAL; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; REACTION ANALYSIS; REVIEW; SOLID; SOLVATE;

EID: 71049173732     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.57283     Document Type: Review

References (62)

1. Paul EL, Tung HH, Midler M. Organic crystallization processes. Powder Technol 2005;150:133-143
2. Gardner CR, Walsh CT, Almarsson Ö. Drugs as materials: Valuing physical form in drug discovery. Nat Rev Drug Disc 2004;3:926-934
3. Byrn SR, Pfeiffer RR, Stowell JG. Solid-state chemistry of drugs. West Lafayette; SSCI: 1999.
4. Brittain H, editor. Polymorphism in pharmaceutical solids. Vol.95, New York: Marcel Dekker; 1999.
5. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977;66:1-19.
6. Gould PL. Salt selection for basic drugs. Int J Pharm 1986;33:201-217
7. Kobell FV, Prakt JF. D-glucose: Sodium chloride monohydrate. Chemie 1843;28:489.
8. Wöhler F. Untersuchungen über das Chinon Quinhydrone. Annalen 1844;51:153.
9. Buguet A. Cryoscopy of Organic Mixtures and Addition Compounds. Compt Rend 1910;149:857.
10. Grossmann H. Thiourea. Cryoscopy of organic mixtures and addition compounds. Chemiker-Zeitung 1908;31:1195.
11. Damiani A, De Santis P, Giglio E. The crystal structure of the 1:1 molecular complex between 1,3,7,9-tetramethyluric acids and pyrene. Acta Crystallogr 1965;19:340.
12. Van NJ, Saunder DH. The crystal structure of the molecular complex of 4,4'-dinitrobiphenyl with biphenyl. Acta Crystallogr 1948;1:44.
13. Pekker S, Kovats E, Oszlanyi G, Benyei G, Klupp G. Rotor-stator molecular crystals of fullerenes with cubane. Nat Materials 2005;4:764-767
14. Matthew LP, Magali BH, Michael JZ, Almarsson Ö. Expanding the scope of crystal form evaluation in pharmaceutical science. J Pharm Pharmaceut Sci 2006;9:317-326
15. Nair RH, Sarah J N, Adivaraha J, Swarbreek editors. Co-crystals: design, properties and formulation mechanism, in Encyclopedia of Pharmaceutical Technology, 3rd ed. Vol.1, New York: Informa Healthcare; 2007. p. 615.
16. Serajuddin AT, Pudipeddi M, Stahl PH, Wermuth CG, editors, Handbook of pharmaceutical salts. Weinheim: Wiley-VCH; 2002. p. 138.
17. Andrew VT, Sam Motherwell WD, Jones W. Physical stability enhancement of theophylline via co crystallization. Int J Pharm 2006;320:114-123
18. Orl A, Michael JZ. Crystal engineering of the composition of pharmaceutical phases, do pharmaceutical co-crystals represent a new path to improve medicine? Chem Comm 2004;:1889-1896
19. Koji S, Noriyuki T, Ryusuke T, Yoshiki H, Katsuhide T. Dissolution improvement and the mechanism of the improvement from co crystallization of poorly water-soluble compounds. Pharm Res 2006;23:1144-1156
20. Morrissette S, Almarsson O, Peterson M, Remenar J. High-throughput crystallisation: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 2004;56:275-300.
21. Magali BH, Matthew LP, Lisa AS, Sherry LM, Vetter A, Hector G, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007;67:112-119
22. Salole EG, Al-Sarraj FA. Spiranolactone crystal forms. Drug Develop Ind Pharm 1985;11:855-864
23. Trask AV, Motherwell WD, Jones W. Solvent-drop grinding: Green polymorph control of co-crystallization. Chem Comm 2004;890-891
24. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997;14:1691-1698
25. Tong P, Zografi G. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J Pharm Sci 2001;90:2372-2373
26. Warwick B, Dehghani F, Foster NR, Biffin JR. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-1302
27. Sekiguchi K, Obi AT. Studies on absorption of eutectic mixture: I: A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 1961;9:866-872
28. Emara LH, Badr RM, Elbary AA. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Develop Ind Pharm 2002;28:795-807.
29. Kai T, Akiyama Y, Nomura S, Sato M. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem Pharm Bull 1996;44:568-571
30. Juppo AM, Boissier C, Khoo C. Evaluation of solid dispersion particles prepared by SEDS. Int J Pharm 2003;250:385-401.
31. Forster A, Hempenstall J. Rades T. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 2001;53:303-315
32. Mirza S, Heinämäki J, Miroshnyk I, Yliruusi J. Co-crystals: An emerging approach to improving properties of pharmaceutical solids. Eur J Pharm Sci 2008;34:S16-7.
33. Burton WK, Cabrera N, Frank FC. The growth of crystals. Phil Tran R Soc Lond A 1951;243:299-358.
34. Ning S, Michael JZ. The role of co-crystals in pharmaceutical science. Drug Discov Today 2008;13:440-446
35. Portalone GC. First example of co-crystals of polymorphic maleic hydrazide. J Chem Crystallogr 2004;34:609-612
36. Aakeröy CB. Beatty AM, Helfrich BA, Nieuwenhuyzen M. Do polymorphic compounds make good cocrystallising agents? A structural case study that demonstrates the importance of synthon flexibility. Cryst Growth Des 2003;3:159-165 (Pubitemid 37130600)
37. Zaworotko M. Polymorphism in co-crystals and pharmaceutical co-crystals. Florence: XX Congress of the International Union of Crystallography: 2005.
38. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007;59:617-630
39. Mutalik S, Prambil A, Krishnan M, Achuta NU. Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan based solvent change approach. Int J Pharm 2008;350:279-290
40. Tiwary AK, Swarbreek editor. Crystal habit changes and dosage form performance. Encyclopedia of Pharmaceutical Technology, 3rd ed. Vol.2, New York, London: Informa Healthcare; 2007. p. 820.
41. Nair RH, Ron CK, Brent DS, Jonathan MM, Swarbreek editors. Crystallization: General principles and significance on product development. Encyclopedia of Pharmaceutical Technology, 3rd ed. Vol.2, London: Informa Healthcare; 2007. p. 834.
42. Kiang YH, Yang CY, Staples RJ, Jonan J. Crystal structure, crystal morphology, and surface properties of an investigational drug. Int J Pharm 2009;368:76-82.
43. Rasenac N, Muller BW. Properties of ibuprofen crystallized under various conditions: A comparative study. Drug Develop Ind Pharm 2001;27:803-809
44. Jingkang W, Yongli W, Ying B, Effects of solvent and impurity on crystal habit modification of 11á-hydroxy-16á,17á-epoxyprogesteron. Chin J Chem Eng 2007;15:648-653
45. Aaltonen J, Alleso M, Mirza S, Koradia V, Gorden KC, Rantanen J. Solid form screening: A review. Eur J Pharm Biopharm 2009;71:23-37.
46. Higuchi T, Roy K. Study of possible complex formation between macromolecules and certain pharmaceuticals I. Polyvinylpyrrolidone (PVP) with sulfathiazole, procaine hydrochloride, sodium salicylate, benzylpenicillin, chloramphenicol, mandelic acid, caffeine, theophylline, and cortisone. J Am Pharm Assoc 1954;43:393-397
47. Higuchi T, Roy K. Study of possible complex formation between macromolecules and certain pharmaceuticals II: Polyvinylpyrrolidone with p-aminobenzoic acid (PABA), aminopyrine, benzoic acid, salicylic acid, phydroxybenzoic acid, hydroxybenzoic acid, citric acid, and Phenobarbital. J Am Pharm Assoc 1954;43:398-401.
48. Zerkowski JA. Solid-state structures of 'Rosette' and 'Crinkled Tape' motifs derived from the cyanuric acid melamine lattice. J Am Chem Soc 1992;114:5473-5475
49. Fleischmann SG. Crystal engineering of the composition of pharmaceutical phases: Multiple component crystalline solids involving carbamazepine. Cryst Growth Des 2003;3:909-919
50. Childs SL. Crystal engineering approach to forming co-crystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 2004;126:13335-13342
51. Remenar JF. Crystal engineering of novel co-crystals of a Triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125:8456-8457
52. Remenar JF. Novel Crystalline forms of conazoles and methods of making and using the same. USP0070551, 2005.
53. Zegarac M. Pharmaceutically acceptable co crystalline forms of sildenafil. WO080362 A1, 2007.
54. Puschner B. Assessment of melamine and cyanuric acid toxicity in cats. J Vet Diag Invest 2007;19:616-624
55. Portero A, Ropez R, Vila-jato JL. Effect of chitosan and chitosan glutamate on enhancing the dissolution properties of poorly watersoluble drug nifedipine. Int J Pharm 1998;175:75-84.
56. Reji T, Srinivasa RG, Kulkarni GU, Rao CNR. Hydrogen bonding patterns in the co-crystals of 5-nitrouracil with several donor and acceptor molecules. Beilstein J Org Chem 2005;1:15.
57. Basavoju S, Bostrom D, Velaga SP. Indomethacin-saccharin co crystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2007;25:530-540
58. Lara-Ochoa F, Espinosa-Perez G. Crystals and patents. Cryst Growth Des 2007;7:1213-1215
59. Devarakonda SN, Vyas K, Bommareddy SR, Padi PR, Raghupathy B. Aripiprazole co-crystals. WO/2007/092779, 2007.
60. www.faqs.org/patents/app/20090176983,Tenofovir Disoproxil Hemi- Fumaric Acid Co-Crystal, 2007.
61. Childs S, Co-Crystallization methods WO/2007/038524, 2007.
62. Andrew V. Overview of pharmaceutical Co-crystals as intellectual property. Mol Pharmaceutics 2007;4:301-309